Mucosal Priming with Replicative Tiantan Vaccinia and Systemic Boosting with Dna Vaccine Raised Strong Mucosal and Systemic Hiv-Specific Immune Responses

Xianggang Huang,Lianxing Liu,Li Ren,Chao Qiu,Yanmin Wan,Jianqing Xu
DOI: https://doi.org/10.1016/j.vaccine.2007.08.066
IF: 4.169
2007-01-01
Vaccine
Abstract:An effective vaccine strategy for HIV-1 will probably require the induction and maintenance of both humoral and cellular immunity at mucosal and systemic sites. We tested a new prime-boost approach of intranasal priming with 3×106 PFU of replicative recombinant Tiantan vaccinia virus (rTTV) and intramuscular boosting with 100μg DNA plasmid expressing HIV-1 Gag in BALB/c mice along with other strategies. Our data demonstrated that intranasal priming with replicative recombinant Tiantan vaccinia and intramuscular boosting with DNA vaccine raised the highest vaginal IgA and systemic T-cell responses, and modest lung IgA and sera IgG responses among all vaccination regimens; each vaccination regimen generated its own imprint of the most preferential T-cell receptor usage of Vβ. These results demonstrate that the combination of intranasal priming with replicative recombinant Tiantan vaccinia and intramuscular boosting with DNA vaccine is a preferable regimen for induction of both T-cell and humoral immune responses at mucosal and systemic sites.
What problem does this paper attempt to address?